Cyclerion Therapeutics Announces September 4 Record Date For Contingent Value Rights Distribution To Common And Series A Preferred Holders In Connection With Planned Korsana Biosciences Merger

Benzinga News-desk www.benzinga.com Neutral 92.4%

Neg 0% Neu 92.4% Pos 0%

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001755237/000119312526365150/d376250d8k.htm

Comments

No comments yet. Be the first!